Estrone-Conjugated PEGylated Liposome Co-Loaded Paclitaxel and Carboplatin Improve Anti-Tumor Efficacy in Ovarian Cancer and Reduce Acute Toxicity of Chemo-Drugs
DOI: https://doi.org/10.2147/IJN.S362263
IF: 7.033
2022-07-07
International Journal of Nanomedicine
Abstract:Huan Tang, Yizhuo Xie, Ming Zhu, Juan Jia, Rui Liu, Yujia Shen, Yucui Zheng, Xin Guo, Dongfanghui Miao, Jin Pei Department of Biopharmacy, School of Pharmaceutical Sciences, Jilin University, Changchun, People's Republic of China Correspondence: Jin Pei, Department of Biopharmacy, School of Pharmaceutical Sciences, Jilin University, 1163 Xinmin Street, Changchun, 130021, People's Republic of China, Tel +86 431 85619725, Email Purpose: Ovarian cancer is the most lethal gynecologic malignancy. The combination of paclitaxel (PTX) and carboplatin (CBP) is the first-line remedy for clinical ovarian cancer. However, due to the limitations of adverse reaction and lacking of targeting ability, the chemotherapy of ovarian cancer is still poorly effective. Here, a novel estrone (ES)-conjugated PEGylated liposome co-loaded PTX and CBP (ES-PEG-Lip-PTX/CBP) was designed for overcoming the above disadvantages. Methods: ES-PEG-Lip-PTX/CBP was prepared by film hydration method and could recognize estrogen receptor (ER) over-expressing on the surface of SKOV-3 cells. The characterizations, stability and in vitro release of ES-PEG-Lip-PTX/CBP were studied. In vitro cellular uptake and its mechanism were observed by fluorescence microscope. In vivo targeting effect in tumor-bearing mice was determined. Pharmacokinetics and biodistribution were studied in ICR mice. In vitro cytotoxicity and in vivo anti-tumor efficacy were evaluated on SKOV-3 cells and tumor-bearing mice, respectively. Finally, the acute toxicity in ICR mice was explored for assessing the preliminary safety of ES-PEG-Lip-PTX/CBP. Results: Our results showed that ES-PEG-Lip-PTX/CBP was spherical shape without aggregation. ES-PEG-Lip-PTX/CBP exhibited the optimum targeting effect on uptake in vitro and in vivo. The pharmacokinetics demonstrated ES-PEG-Lip-PTX/CBP had improved the pharmacokinetic behavior. In vitro cytotoxicity showed that ES-PEG-Lip-PTX/CBP maximally inhibited SKOV-3 cell proliferation and its IC 50 values was 1.6 times lower than that of non-ES conjugated liposomes at 72 h. The in vivo anti-tumor efficacy study demonstrated that ES-PEG-Lip-PTX/CBP could lead strong SKOV-3 tumor growth suppression with a tumor volume inhibitory rate of 81.8%. Meanwhile, acute toxicity studies confirmed that ES-PEG-Lip-PTX/CBP significantly reduced the toxicity of the chemo drugs. Conclusion: ES-PEG-Lip-PTX/CBP was successfully prepared with an optimal physicochemical and ER targeting property. The data of pharmacokinetics, anti-tumor efficacy and safety study indicated that ES-PEG-Lip-PTX/CBP could become a promising therapeutic formulation for human ovarian cancer in the future clinic. Graphical Keywords: ovarian cancer, combination therapy, drug delivery system, liposome, estrogen receptor Graphical Ovarian cancer is the fifth leading cause of cancer-related mortality in women worldwide with the ratio of 15–20 per 100,000. 1,2 It is the most lethal malignancy in all the gynecological tumors. 3 Less than one-half of patients survive for more than five years after diagnosis. 4 Current treatment for ovarian cancer remains surgery followed by combined chemotherapy. 5,6 The therapeutic regimen appears to be initially effective in a high number of patients, but nearly 70% of the people suffer a relapse within a few months after initial treatment. 7,8 Combination chemotherapy for the treatment of cancer has been widely applied to clinic, which could increase therapeutic efficacy and reduce the drug resistance over single-drug chemotherapy. 9–12 Paclitaxel (PTX) and carboplatin (CBP) combined chemotherapy is first-line cancer chemotherapy regimen for ovarian cancer. 13,14 PTX induces cell cycle arrest at the G2/M phase by suppressing dynamic instability of microtubules resulting in cell apoptosis, whereas CBP interferes with DNA transcription by reacting with DNA to form cross-linking DNA, which triggers apoptosis. 15 Both drugs play different mechanisms in the inhibition growth of ovarian cancer, 16,17 thereby producing a synergistic anti-tumor effect via triggering different apoptosis signaling pathways and the potential to decrease the drug resistance. 18 While like all the chemo-therapy, the PTX and CBP combined chemotherapy also has severe side effects and adverse reactions, 19 such as bone marrow inhibition, neuropathy and kidney toxicity. 20,21 Therefore, a more effective and better-tolerated chemo-therapy is urgently needed in clinical. Nanoparticle drug delivery system, such as liposomes, 22 micelles, 23 dendrimers, 24 nanocapsules, 25 nanotubes 26 and art -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology